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Case Presentation
Dr Force: A 46-year-old woman initially presented to a local emergency room
in February 2002 with shoulder and back pain. She had a chest radiograph that
demonstrated an abnormality. A computed tomographic (CT) scan of the chest was
performed to characterize this lesion. Her medical history was unremarkable and her
surgical history was significant for a basal skin cancer that was removed from her
left eyebrow and a left breast lumpectomy for a benign lesion.
Dr Glazer: The chest radiograph is remarkable for a well-defined mass within
the left upper lobe, which is well visualized on this CT scan (Figure 1). It has
slightly lobulated borders and it abuts the lateral chest wall with no obvious rib
destruction or chest wall invasion. It is relatively homogeneous except for some
small low attenuation areas laterally, which may represent areas of necrosis within
the mass. There is no calcification and no fat within the mass (Figure 2). There is
a mildly enlarged lymph node in the right hilum, but no other lymphadenopathy
seen. No other pulmonary nodules or effusions were seen (Figure 3) and the images
in the upper abdomen were normal.
Dr Force: The patient subsequently underwent a fine needle aspiration of this
lesion at an outside hospital, which revealed a fetal type adenocarcinoma or
pulmonary blastoma. She then underwent an extensive radiographic workup that
included a CT scan of the abdomen and pelvis, which showed some small hepatic
lesions and a large mass in her pelvis that looked like it was coming from the uterus.
She had a right upper quadrant ultrasound that showed the liver lesions to be
consistent with simple cysts. She also had an MRI of her brain and a PET, which
failed to show any evidence of metastases.
Dr Siegel: The F-18 fluorodeoxyglucose positron emission tomography (FDG-
PET) study demonstrates fairly intense uptake in the left upper lobe mass (Figure 4).
The standardized uptake value in this mass was 13, which is well in the malignant
range. There were no metastases identified on this study; however, in reviewing the
study today, there is a suspicion of faint uptake in mediastinal lymph nodes, but
there appears to be no correlate for those nodes on the CT. There is very faint uptake
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in the pelvic mass, which was tremendously displacing the
bladder. That is nonspecific, and it is certainly consistent
with a benign leiomyoma of the uterus.
Dr Cooper: Did you think that the uterine lesion was
benign?
Dr Force: It was thought that it was consistent with a
leiomyoma. However, I’m not sure how well PET can
differentiate between a sarcoma versus myoma versus
carcinoma.
Dr Siegel: The bigger problem would be with false
positive results, because some leiomyomas have increased
FDG uptake on PET.
Dr Cooper: If this should turn out to be a benign me-
tastasizing leiomyoma, it doesn’t make any difference be-
cause you’re going to take out the pulmonary lesion any-
way. Is there anything that you could have turned up in the
pelvis that would have altered how you managed the pul-
monary lesion? It sounds like the answer is no.
Dr Force: I think if she had a leiomyosarcoma in the
uterus, that would need to be dealt with. However, the
negative PET findings made a leiomyosarcoma very un-
likely. There was a distinct difference in PET uptake be-
tween the lung and the uterine lesion. Since the workup for
metastatic disease was negative, the patient was taken to the
operating room, where she underwent a bronchoscopic ex-
amination, which showed no endobronchial abnormalities.
A limited posterolateral left thoracotomy was performed.
When the left side of the chest was entered, inflammatory
adhesions were seen tethering the tumor to the pleura, but
the tumor actually fell away from the pleura quite easily.
The visceral pleura did not appear to be grossly involved by
the tumor. We initially started the dissection in the fissure
and sent off some interlobar lymph nodes as well as some
peribronchial lymph nodes for a frozen section. These came
back negative for metastatic disease. We completed the left
upper lobectomy, and the patient was transferred to the
recovery unit. She did very well and was discharged home
on the sixth postoperative day. Perhaps we could review
pathology at this point.
Figure 3. Preoperative chest CT, lung window.
Figure 4. Preoperative FDG PET imaging.
Figure 1. Preoperative chest radiograph.
Figure 2. Preoperative chest computed tomography, mediastinal
window.
Clinical-Pathologic Conference Force and Patterson
1248 The Journal of Thoracic and Cardiovascular Surgery ● November 2003
Dr Ritter: Here is the lobectomy specimen and the
cross-section of the tumor (Figure 5). As you can see, the
tumor is in the periphery above the pleura and the tumor
itself is tan with central necrosis and hemorrhagic areas.
This is typical of this type of tumor. It is well circumscribed,
and a high-power view shows that it is composed of gland-
like spaces and columnar cells (Figure 6). The cells of this
tumor have atypical nuclei as well as subnuclear vascular-
ization, which looks like a secretory type of endometrium.
The other morphologic feature of this kind of tumor is the
presence of squamoid nests of cells called morules (Figure
7).
Dr Force: Looking at these slides, one can see how
these tumors got their names as fetal type because they had
characteristics similar to fetal lung.
Dr Ritter: There are three types of tumors that are in-
cluded in a group with the name “pulmonary blastomas.”
There are monophasic and biphasic types and then there is
a pleuropulmonary blastoma. The latter is a tumor that Dr
Louis Dehner described about 15 years ago. It is actually a
different sort of entity. It is usually seen in children and is
similar to other kinds of childhood blastomas. It looks like
Wilms tumor and has associations with other kinds of
childhood malignant tumors such as rhabdomyosarcoma.
The monophasic pulmonary blastoma is the type of tumor
that this patient has.
Dr Force: Is that the same thing as a well-differentiated
fetal adenocarcinoma?
Dr Ritter: Those terms are used synonymously. Hav-
ing looked at autopsy lungs from fetuses, I think that it
looks more like endometrium than it does like fetal lung,
and a lot of people have made that comparison. Most
patients with this tumor are in their 30s and 40s, which is
quite a bit younger than is seen with “typical” lung
cancer. Most of the patients are smokers and I don’t think
it has ever been reported in anybody less than 10 years of
age.
Dr Roper: In the childhood cases you were talking
about, is that generally called lipoblastoma because it is
essentially benign?
Dr Ritter: No, that is something different. The lesion in
children is really a very aggressive malignancy. It has
features of other childhood tumors such as rhabdomyosar-
coma or some other childhood sarcoma and, again, may
have a familial association.
Dr Govindan: I was under the impression that this was
just a variation of pleural pulmonary blastoma?
Dr Ritter: If you do molecular studies on these, you can
see that they express Clara cell antigens or surfactant so
they look like they come from distal airway cells, like
bronchiolar or alveolar epithelium. These mark like carci-
nomas, as opposed to the pleuropulmonary blastomas,
which seem to be some kind of sarcomatoid lesion that
probably comes from primitive fibroblastic cells.
Dr Force: These tumors also have a much better prog-
nosis than pleuropulmonary blastomas.
Dr Ritter: Also a much better prognosis than the bipha-
sic ones, which are even less common. I think in 10 years
Figure 5. Surgical pathology gross photo. Figure 6. Surgical pathology histologic photo.
Figure 7. Surgical pathology histologic photo.
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we have only seen about three or four of those tumors.
These cases behave about the same as any form of lung
cancer, stage for stage. In most of the patients the tumor is
T2 sized by the time it is discovered. But most of these
tumors are way off in the periphery of the lung like this.
Dr Cooper: I don’t think I have seen one of these so
called pleuropulmonary blastomas. Are they associated with
pleura or is that a histologic description?
Dr Ritter: No, most of them are subpleural and may
present as a pleural mass. The pleuropulmonary blastoma is
almost exclusively a pediatric condition. We see these rare
lesions frequently because Dr Dehner, the chief of pathol-
ogy, runs the pleuropulmonary blastoma registry. We have
seen only one adult with a pleuropulmonary blastoma. Un-
less you operate on children, you will never see this lesion.
Dr Force: Dr Govindan, I know that you evaluated this
patient for neoadjuvant therapy. What do you think is the
role of preoperative therapy for larger lesions, perhaps T3
tumors or those with nodal metastases? Do you treat them
like adenocarcinomas?
Dr Govindan: I reviewed this subject rather extensively
over a year and a half ago when I was referred a patient that
Dr Ritter just mentioned. The patient had advanced disease
and had already received a variety of chemotherapy agents.
There have only been a few studies looking at chemother-
apy and radiation in these tumors and they usually report a
poor outcome. Given the morphology of the tumor and the
fact that the patient appeared to have T2 N0 disease, we
elected to treat it like adenocarcinoma of the lung, which is,
I think, what most oncologists would do. In the patient
being discussed, we elected not to administer any induction
therapy because we thought she had a favorable lesion
amenable to complete resection. As it turned out, she had a
T2 N0 lesion. If this were classified as a non-small cell lung
cancer, she would be eligible for an adjuvant chemotherapy
protocol. Since the diagnosis is pulmonary blastoma, I don’t
think we can make a compelling argument for any further
treatment.
Dr Force: To sum up this rare tumor, pulmonary blas-
toma comprises only 0.5% of all lung cancers. This tumor
was first recognized by Barret and Barnard in 1945 and was
termed embryoma of the lung due to its similarity to fetal
lung tissue. This tumor was shown to have both epithelial
and mesenchymal components. The term embryoma of the
lung was renamed pulmonary blastoma (PB) by Spencer in
1961 in his report of three additional cases.1 Kradin iden-
tified a subgroup in 1982 consisting only of an epithelial
component. This tumor is now known as well-differentiated
fetal adenocarcinoma (WDFA). Manivel identified a second
subgroup in 1988. This tumor, called pleuropulmonary
blastoma (PPB), was shown to occur in children and
consisted of only malignant mesenchymal cells. Pulmo-
nary blastoma is now recognized in three forms: one
biphasic type (PB) and two monophasic types (WDFA
and PPB).2,3
The majority of patients with PB and WDFA are adults
with a median age of 40 years. PPB, on the other hand,
usually presents in childhood with a median age of 3 years.
Although the small number of cases prevents defining an
exact causative agent, the majority of patients have a history
of tobacco use. Congenital cystic lung disease has been
suggested as a predisposing factor in the case of PPB.
Presenting symptoms are similar to those of bronchogenic
carcinoma and consist of respiratory complaints, chest pain,
pleural effusion, and pneumothorax. No serum tumor mark-
ers have been shown to be consistently elevated in these
tumors.4
Anatomic resection, lobectomy, or pneumonectomy is
the treatment of choice for monophasic and biphasic pul-
monary blastomas. Case reports on the use adjuvant che-
motherapy, usually cisplatin based, and adjuvant radiation
have reported a wide range of response rates; but, the
overall numbers are too small to draw any definitive con-
clusions. The overall survival for all three types of tumor is
poor with only 33%, 16%, and 8% of patients alive at 2, 5,
and 10 years, respectively. Among the subgroups, PPB has
the worst prognosis. WDFA appears to have the best prog-
nosis with a median survival of almost 3 years. Some
investigators have suggested that WDFA can be separated
into high and low grades based on several histopathologic
features. The patients with low-grade lesions tend to have a
considerably longer survival than those with high-grade
tumors.5
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